JHJeong Woo Hong

Jeong Woo Hong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeong Woo Hong has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Chang Min Lee

    Department of Internal Medicine, Gyeongsang National University College of Medicine, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea

    1 shared publication
  • Chang Yoon Ha

    Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju 52727, Korea

    1 shared publication
  • Hong Jun Kim

    Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju

    1 shared publication
  • Hyun Chin Cho

    Department of Internal Medicine, Gyeongsang National University Hospital, Jinju 52727, Republic of Korea

    1 shared publication
  • Hyun Jin Kim

    Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea

    1 shared publication
  • Hyun Seon You

    Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Gangnam-ro 79, Jinju, Gyeognam, 660-702, South Korea.

    1 shared publication

Latest Publications

  • Open Access

    Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury

    by Wan Soo Kim, Sang Soo Lee, Chang Min Lee, Hong Jun Kim, Chang Yoon Ha, Hyun Jin Kim, Tae Hyo Kim, Woon Tae Jung, Ok Jae Lee, Jeong Woo Hong, et al.

    The risk of anti-tuberculosis (TB) drug-induced liver injury (DILI) in patients with chronic viral hepatitis (CVH) is not clear. The aim of this study was to investigate incidence and risk factors associated with TB DILI in CVH and non-CVH patients. Retrospectively, a total of 128 CVH patients who received anti-TB medication from January 2005 to February 2014 were reviewed. Among these, 83 patients had hepatitis B virus (HBV), 41 patients had hepatitis C virus (HCV) and 4 patients were dual hepatitis B and hepatitis C virus co-infected (HBV + HCV) with 251 non-CVH patients who received anti-TB medication selected as the controls. There were no human immunodeficiency virus co-infected patients. Risk factors for DILI were analyzed using cox regression analysis. The incidence of DILI was significantly higher in the HCV group (13/41 [31.7 %], p < 0.001) and HBV + HCV groups (3/4 [75.0 %], p = 0.002) compared to the control group (25/251 [10.0 %]). The incidence of transient liver function impairment in the hepatitis B virus group was higher than in the control group (18/83 [21.7 %] vs. 27/251 [10.8 %] p = 0.010), but not in DILI (11/83 [13.3 %] vs. 25/251 [10.0 %], p = 0.400). In total patients, HCV, HBV + HCV co-infection, older age, and baseline liver function abnormality were independent factors of DILI. It is recommended to carefully monitor for DILI in patients with HCV or HBV/HCV co-infection, older age, and baseline liver function abnormality.